Friday, July 15, 2022

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Thermo Fisher Scientific Inc. (TMO), and TotalEnergies SE (TTE). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
 
You can see all of today’s research reports here >>>

Eli Lilly shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+42.6% vs. +17.7%) on the back of a solid portfolio of core drugs in diabetes, autoimmune diseases and cancer. Lilly’s revenue growth is being driven drugs like Trulicity, Taltz, and others.

It is regularly adding promising new pipeline assets through business development deals. It has an exciting pipeline of potential new medicines including tirzepatide for type II diabetes and donanemab for early Alzheimer's disease. Both candidates have multibillion-dollar sales potential.

However, generic competition for several drugs, rising pricing pressure in the United States mainly on key drug, Trulicity, and price cuts in some international markets like China, Japan and Europe are some top-line headwinds.

(You can read the full research report on Eli Lilly here >>>)

Thermo Fisher shares have outperformed the Zacks Medical - Instruments industry over the past year (+1.4% vs. -25.8%). This reflects the favorable grwoth outlook for the company’s in the Analytical Instruments and the Laboratory Products and Biopharma Services segments.

The company’s strategic acquisitions of PPD, Inc. and PeproTech raise investors’ confidence. Thermo Fisher’s accelerated investments to expand bioproduction capacity also buoy optimism. The upbeat guidance for 2022 is indicative that this growth momentum will continue.

However, the year-over-year decline in revenues in the Specialty Diagnostics segment is disappointing. The contraction of both margins does not bode well either.

(You can read the full research report on Thermo Fisher here >>>)

TotalEnergies shares have gained +13.8% over the past year against the Zacks Oil and Gas - Refining and Marketing industry’s gain of +36.4%. The company is gaining from new startups, an increase in commodity prices, well-spread LNG assets, and an expanding upstream portfolio that has exposure to fast-growing hydrocarbon-producing regions.

TTE streamlines its portfolio through acquisitions, partnerships and divestitures. It is making regular investments to expand the renewable operation and aims to achieve net-zero emissions by 2050. TTE has enough liquidity to meet debt obligations.

However, TTE’s profitability is likely to have been impacted by natural decline in the oil and natural gas fields. TTE remains exposed to acquisition-related risks as these assets contribute a sizable volume to production. TTE has operations in some politically-troubled regions and the ongoing Russia and Ukraine conflict might affect profitability.

(You can read the full research report on TotalEnergies here >>>)

Other noteworthy reports we are featuring today include Amgen Inc. (AMGN), Prologis, Inc. (PLD), and Marathon Petroleum Corporation (MPC).

Sheraz Mian
 
Director of Research

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>